IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 7,323,493 Issue Date: January 29, 2008

Application No. 09/446,601

Patentees: Bernard Abramovici, Jean-Claude Gautier, Jean-Claude Gromenil, and

Jean-Marie Marrier

Title: SOLID PHARMACEUTICAL COMPOSITION CONTAINING

BENZOFURAN DERIVATIVES

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that the correspondence below is being transmitted via the USPTO's electronic filing system in accordance with 1.6(a)(4), on the date indicated below.

Date of Deposit August 2, 2012

Printed Name of Person

Signing Certificate <u>Brian Pritchett</u>

Signature /Brian Pritchett/

Mail Stop Hatch-Waxman PTE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO REQUIREMENT FOR ELECTION OF APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. § 156 AND PURSUANT TO 37 C.F.R. § 1.785(b)

This is in response to the Notice of Final Determination and Requirement for Election mailed on July 12, 2012, by the United States Patent and Trademark Office, setting a one month period for response set to expire on August 12, 2012. This response is timely filed.

Pursuant to 37 C.F.R. § 1.785(b), Applicant elects U.S. Patent No. 5,223,510 for patent term extension based upon the regulatory review of MULTAQ® (dronedarone hydrochloride), i.e., Applicant does <u>not</u> elect the above-referenced U.S. Patent No. 7,323,493.

It is believed that no fees are due in connection with this submission. However, should it be determined that fees are due, the Commissioner is authorized to charge any necessary fees to Deposit Account No. 18-1982, upon which the undersigned is authorized to draw.

Respectfully submitted,

August 2, 2012

Date

/Kelly L. Bender/
Kelly L. Bender, Reg. No. 52,610
Attorney for Applicants

sanofi-aventis U.S. Inc.
U.S. Patent Operations
55 Corporate Drive
Mail Stop – 55A-505A
Bridgewater, New Jersey 08807
Telephone (908) 981-6782
Telefax (908) 981-7832

Sanofi Docket No. IVD000994 US PCT